<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>20(1)</volume><submitter>Liu Y</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>The risk factors contributing to embolism in cardiac myxoma (CM) are yet controversial. This systematic review and meta-analysis aimed to clarify the risk factors of embolism for the CM patients.&lt;h4>Methods&lt;/h4>PubMed, Embase, Cochrane library, Web of Science, China National Knowledge Infrastructure, Wan Fang, and Wei Pu databases were searched from inception to June 2019. Statistical analysis was conducted using Stata version 14.0. The pooled odds ratio or mean difference with 95% confidence interval was estimated for each risk factor.&lt;h4>Results&lt;/h4>Herein, 12 studies, encompassing 1814 patients, were included. The pooled results suggested that New York Heart Association (NYHA) class I/II (P &lt; 0.01), hypertension (P = 0.03), irregular tumor surface (P &lt; 0.01), tumor in</pubmed_abstract><journal>BMC cardiovascular disorders</journal><pagination>348</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7382866</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Risk factors of embolism for the cardiac myxoma patients: a systematic review and metanalysis.</pubmed_title><pmcid>PMC7382866</pmcid><pubmed_authors>Ping L</pubmed_authors><pubmed_authors>Liu Y</pubmed_authors><pubmed_authors>Guo L</pubmed_authors><pubmed_authors>Wang J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Risk factors of embolism for the cardiac myxoma patients: a systematic review and metanalysis.</name><description>&lt;h4>Background&lt;/h4>The risk factors contributing to embolism in cardiac myxoma (CM) are yet controversial. This systematic review and meta-analysis aimed to clarify the risk factors of embolism for the CM patients.&lt;h4>Methods&lt;/h4>PubMed, Embase, Cochrane library, Web of Science, China National Knowledge Infrastructure, Wan Fang, and Wei Pu databases were searched from inception to June 2019. Statistical analysis was conducted using Stata version 14.0. The pooled odds ratio or mean difference with 95% confidence interval was estimated for each risk factor.&lt;h4>Results&lt;/h4>Herein, 12 studies, encompassing 1814 patients, were included. The pooled results suggested that New York Heart Association (NYHA) class I/II (P &lt; 0.01), hypertension (P = 0.03), irregular tumor surface (P &lt; 0.01), tumor in</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Jul</publication><modification>2025-05-29T14:36:54.202Z</modification><creation>2024-10-19T04:28:04.086Z</creation></dates><accession>S-EPMC7382866</accession><cross_references><pubmed>32711463</pubmed><doi>10.1186/s12872-020-01631-w</doi></cross_references></HashMap>